Physician profile
Malay Agrawal
NPI 1376530881
$1,108.25
in general payments reported to CMS, 2019-2025
9 companies · $25.00 in 2025
The $25.00 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.40 · 2020: $199 · 2021: $103 · 2022: $391 · 2023: $111 · 2024: $236 · 2025: $25.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $612.95 | 2019-2024 | Lifevest |
| Irhythm Technologies, INC. | $140.14 | 2024 | Zio Xt Patch, Zio Monitor |
| Astrazeneca Pharmaceuticals LP | $130.41 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $74.29 | 2022-2024 | Xarelto |
| Abbott Laboratories | $48.43 | 2023-2025 | Triclip, Cardiomems |
| Novartis Pharmaceuticals Corporation | $41.65 | 2022-2024 | |
| Philips North America LLC | $20.83 | 2022 | |
| Glaxosmithkline, LLC. | $20.19 | 2023 | Arexvy, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $19.36 | 2023 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malay Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.